Singjai20/iStock via Getty Images Cara Therapeutics ( NASDAQ: CARA ) said that it will seek strategic alternatives after its pruritus candidate, difelikefalin, failed in a key trial. Difelikefalin did not demonstrate a meaningful clinical benefit at any dose versus placebo in the KOURAGE-1 Part A trial. As a result, the company will wind down the phase 2/3 program.
The drug was under investigation for prurirus, also known as itching, associated with notalgia paresthetica. As of March 31, Cara had $70M in cash, cash equivalents, and marketable securities. More on Cara Therapeutics Cara Therapeutics GAAP EPS of -$0.
56 misses by $0.17, revenue of $2.14M beats by $0.
45M Cara Therapeutics Q1 2024 Earnings Preview Seeking Alpha’s Quant Rating on Cara Therapeutics Historical earnings data for Cara Therapeutics Financial information for Cara Therapeutics.
